A recent article in the Wall Street Times rocked the pharmaceutical world by claiming that one of the world’s biggest drug companies, Pfizer, will be leaving its longtime Manhattan headquarters. Headline Only Readers grabbed up this tidbit without reading the rest of the article and claimed the company was leaving the city entirely. Chicken Littles, for the win.
In fact, the article simply stated Pfizer would be moving to a new office building. They’re not even leaving the borough, much less the Big Apple. But there is an interesting tidbit buried in the Official Story. While Pfizer has not found new digs yet - and won’t complete the move until at least 2019 in any case - the company has said it plans to lease rather than buy the real estate in .
Is that move a harbinger of the company’s expectation that things in the U.S. medical market are about to change?
That’s not the reason they’re giving for the move. According to various media reports, Pfizer is moving to “bring our building up to modern standards…” which will “…take a significant investment … but in terms of capital investment, that’s not where we want to focus.”
So the company wants to invest in making its working areas more modern rather than pushing money into brick and mortar infrastructure and real property. Fair enough, but is that all? Not exactly. In an internal memo, Pfizer let the other shoe drop, saying a “substantial majority” of the current employees will stay in Manhattan, while others would be relocated to “locations in the tri-state area.”
Does that mean there could be some changes in the works for Pfizer, as well as some difficult management decisions and rough headlines? It’s possible, and that brings us back to the question about the medical industry. American consumers are becoming more cognizant of what drug makers are making, doing, selling and, most importantly, how they’re profiting. If the ACA has done anything, it has made more people aware of what the drugs they use actually cost.
These costs have created a groundswell of negative PR for pharmaceutical companies like Pfizer. From time to time, this negative feeling boils over or, in some cases, explodes in a volcanic firestorm of rage. This is a dynamic the folks at Pfizer, and other drug makers, cannot afford to ignore any longer. They need to prepare for the change that is coming, and the company that guesses best what that change will look like can set itself up to win in the new status quo that is coming sooner rather than later.
A recent article in the Wall Street Times rocked the pharmaceutical world by claiming that one of the world’s biggest drug companies, Pfizer, will be leaving its longtime Manhattan headquarters. Headline Only Readers grabbed up this tidbit without reading the rest of the article and claimed the company was leaving the city entirely. Chicken Littles, for the win.
In fact, the article simply stated Pfizer would be moving to a new office building. They’re not even leaving the borough, much less the Big Apple. But there is an interesting tidbit buried in the Official Story. While Pfizer has not found new digs yet - and won’t complete the move until at least 2019 in any case - the company has said it plans to lease rather than buy the real estate in .
Is that move a harbinger of the company’s expectation that things in the U.S. medical market are about to change?
That’s not the reason they’re giving for the move. According to various media reports, Pfizer is moving to “bring our building up to modern standards…” which will “…take a significant investment … but in terms of capital investment, that’s not where we want to focus.”
So the company wants to invest in making its working areas more modern rather than pushing money into brick and mortar infrastructure and real property. Fair enough, but is that all? Not exactly. In an internal memo, Pfizer let the other shoe drop, saying a “substantial majority” of the current employees will stay in Manhattan, while others would be relocated to “locations in the tri-state area.”
Does that mean there could be some changes in the works for Pfizer, as well as some difficult management decisions and rough headlines? It’s possible, and that brings us back to the question about the medical industry. American consumers are becoming more cognizant of what drug makers are making, doing, selling and, most importantly, how they’re profiting. If the ACA has done anything, it has made more people aware of what the drugs they use actually cost.
These costs have created a groundswell of negative PR for pharmaceutical companies like Pfizer. From time to time, this negative feeling boils over or, in some cases, explodes in a volcanic firestorm of rage. This is a dynamic the folks at Pfizer, and other drug makers, cannot afford to ignore any longer. They need to prepare for the change that is coming, and the company that guesses best what that change will look like can set itself up to win in the new status quo that is coming sooner rather than later.
Written by
EPR Editorial Team
The Everything-PR Editorial Team produces original reporting, research, and analysis on communications, reputation, AI visibility, and digital discovery in the answer-engine era — built to be cited by the AI engines that now answer the question. Publishing since 2009.
Other news
See all
EPR Editorial Team · 06/02/2026
Why Virgo PR Is Winning the Mid-Market PR Battle
Virgo PR — the boutique sister brand of 5W AI Communications, founded 2020 by Mike Paffmann — is winning the mid-market PR battle. 150+ launches, $5B+ in client valuations, 20+ IPOs. Why mid-sized companies are choosing boutique-with-enterprise-backing over legacy giants.
EPR Editorial Team · 06/02/2026
DeVries Global: Agency Profile
DeVries Global is a New York-based public relations agency focused on beauty, health and wellness, consumer brands, social and digital influence, and influencer marketing. Founded approximately 35 years ago by Henry DeVries. Global micro-network across NYC, Beijing, Singapore, and London. Part of Omnicom PR since November 2025.
EPR Editorial Team · 06/02/2026
RF Binder: Agency Profile
RF Binder is an independent full-service PR and integrated communications firm founded by Amy Binder. Updated profile clarifying its independence from Ruder Finn since 2016.
Never Miss a Headline
Daily PR headlines, weekly long-form analysis, and our proprietary research drops — straight to your inbox.